Yuliang Zhao

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Zhiwei Wu, Yaling Hu, Miao Xu et al. · The Lancet Infectious Diseases · 2021 · 572 citations · Full text

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial

Bihua Han, Yufei Song, Changgui Li et al. · The Lancet Infectious Diseases · 2021 · 351 citations · Full text

Vaccination, Vaccine Safety, Vaccinology +8

Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials

Gang Zeng, Qianhui Wu, Hongxing Pan et al. · The Lancet Infectious Diseases · 2021 · 284 citations · Full text

Vaccination, Vaccine Safety, Coronary Unit +8

Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial

Xiaofeng Liang, Huaqing Wang, Junzhi Wang et al. · The Lancet · 2009 · 254 citations

Vaccination, Vaccine Safety, Cross-protection +10

Effectiveness of the live attenuated rotavirus vaccine produced by a domestic manufacturer in China studied using a population-based case–control design

Shan-Shan Zhen, Yue Li, Songmei Wang et al. · Emerging Microbes & Infections · 2015 · 55 citations · Full text

Vaccination, Vaccine Safety, Universal Rotavirus +15